{
  "nctId": "NCT04253119",
  "briefTitle": "ART First-line Treatment Durability in Russia",
  "officialTitle": "Retrospective Evaluation of Treatment Durability Among Treatment-naive HIV-infected Individuals Initiated First-line ART in Russia",
  "protocolDocument": {
    "nctId": "NCT04253119",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2020-07-02",
    "uploadDate": "2022-10-06T05:13",
    "size": 617363,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04253119/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 536,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2019-11-26",
    "completionDate": "2022-06-30",
    "primaryCompletionDate": "2022-06-30",
    "firstSubmitDate": "2019-08-02",
    "firstPostDate": "2020-02-05"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Adult patients (\\>18 years of age) with definite HIV-1 infection based on positive lab test and judgement of treating physician according to standards of care\n* Naive to antiretroviral treatment at the time of initiation\n* Viral load of \\>1000 copies/ml at the time of initiation of ART\n* Initiated their first-line ART between February 01 and April 30, 2017\n* Patients are included, if the third component of their first line ART was either NNRTI or boosted PI plus NRTIs\n* Completed follow-up from baseline for at least 96 weeks\n* Signed informed consent\n\nExclusion Criteria:\n\nâ€¢ HIV-2 infection",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "48 Weeks Treatment Durability",
        "description": "Percentage of patients remained on initial therapy without change of the NNRTI or PI agent",
        "timeFrame": "48 weeks"
      }
    ],
    "secondary": [
      {
        "measure": "96 Weeks Treatment Durability",
        "description": "Percentage of patients remained on initial therapy without change of the NNRTI or PI agent",
        "timeFrame": "96 weeks"
      },
      {
        "measure": "Time on Therapy at 48 Weeks",
        "description": "Estimated time on therapy without change of the NNRTI or PI agent at 48 weeks among treatment naive HIV-infected individuals initiated ART (NNRTI, PI)",
        "timeFrame": "48 weeks"
      },
      {
        "measure": "Time on Therapy at 96 Weeks",
        "description": "Estimated time on therapy without change of the NNRTI or PI agent at 96 weeks among treatment naive HIV-infected individuals initiated ART (NNRTI, PI)",
        "timeFrame": "96 weeks"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 3,
      "otherCount": 0,
      "totalCount": 4
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 44,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:21.304Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}